drugset
drugset / Trial / NCT07084896

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

NCT07084896 ↗

Phase 1/2 Active not recruiting 106 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Timeline

Start
2020-06-08
Primary completion
2025-04-17
Completion
2027-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Belantamab mafodotin Monoclonal antibody — —
Subject Nirogacestat Small molecule — —

Indications

plasma cell myeloma